Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Adrenokortikal'nyy rak

Cover Page

Abstract


Адренокортикальный рак (АКР) редкое заболевание, до настоящего момента характеризующееся поздним сроком выявления и неблагоприятным лечебным прогнозом.

D G Bel'tsevich

N S Kuznetsov

V E Vanushko

  1. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. — The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. 1996 Surgery 119:161-170
  2. Dackiw AP, Lee JE, Gagel RF, Evans DB Adrenal cortical carcinoma. 2001 World J Surg 25:914-926
  3. Ng L, Libertino JM Adrenocortical carcinoma: diagnosis, evaluation and treatment. 2003 J Urol 169:5-11
  4. Al-Hawary MM, Francis IR, Korobkin M Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. 2005 Best Pract Res Clin Endocrinol Metab 19:277-292.
  5. Hamrahian AH, loachimescu AG, Remer EM, Motta-Ramirez G, Boga-bathina H, Levin HS, Reddy S, Gill IS, Siperstein A, Bravo EL Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. ] 2005Clin Endocrinol Metab 90:871-877
  6. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Goodsitt M Delayed enhanced CT for differentiation of benign from malignant adrenal masses. 1996 Radiology 200:737-742
  7. Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Roher HD Adrenal involvement in multiple endocrine neoplasia type 1. 2002 World J Surg 26:891-896
  8. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. 2001 Cancer Res 61:6762-6767
  9. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y Rearrangements at the llplS locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical rumors. 1994 J Clin Endocrinol Metab 78:1444-1453
  10. Gicquel C, Le Bouc Y Molecular markers for malignancy in adrenocortical tumors.1997 Horm Res 47:269-272
  11. Wooten MD, King DK Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. 1993 Cancer 72:3145-3155
  12. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. 1998 Cancer 83:2194-2200
  13. Terzolo M, Daffara F, Rossetto R, Buci L, Tagliabue M, Carbone V, Ciuti R, Ferruzzi P, Berruti A, Arvat E, Angeli A, Mannelli M Adjuvant mitotane therapy for adrenal cancer. 2003 Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, , p 571
  14. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson В Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. 2000 Ann Oncol 11:1281-1287
  15. Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K, Eriksson В Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. 2004 Med Oncol 21: 167-177
  16. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. 1990 J Histochem Cytochem 38:1277-1287
  17. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. 1992 Surgery 112:981-986
  18. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I Expression of a multidrug resistance gene in human cancers. -1989 J Natl Cancer Inst 81:116-124
  19. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. -1994 An-ticancer Res 14:1009-1016
  20. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. 1993 Eur J Cancer 29A:1036-1038.
  21. E.Fox, S.E Bates. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Review of Anticancer Therapy, Volume 7, Number 4, April 2007 , pp. 447-459(13).
  22. Walker J, Martin C, Callaghan R Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. 2004 Eur J Cancer 40:594-605

Views

Abstract - 711

PDF (Russian) - 438


Copyright (c) 2009 ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.